All HHS Contracts — February 20, 2026

Two BARDA contracts totaling $365M for biothreat/biotech R&D provide 5-10 year revenue backlogs, with $139M outlayed.

Maximus secures $116M CMS delivery order (potential $198M) for eligibility appeals, with 67% outlayed since 2023.

Small/WOSB firms capture 100% of awards via full open competition, with $365M committed.

Firm fixed price structures in two contracts risk losses if R&D costs exceed $365M obligations.

Outlays lag obligations (45-67% disbursed), exposing to funding delays over long tenors.

$158M unexercised options across contracts could boost total value 33% to $640M.

BARDA 'Other Transaction' and prize vehicles enable follow-on biotech awards post-2028.

BARDA dominates 73% of value with long-term biotech R&D for antibiotics/health solutions.

CMS Time & Materials order underscores reliable operational support funding.

{"entity"=>"Paratek Pharmaceuticals", "reason"=>"Largest award ($265M) with highest option upside ($76M) and longest tenor to 2029.", "trigger"=>"Option exercise or outlay acceleration >$247M"}

{"entity"=>"BARDA Biotech Pipeline", "reason"=>"Concentrated $365M exposure signals broader biothreat trend.", "trigger"=>"New awards or HHS funding bills"}